PaxMedica, Inc. Common Stock (PXMD) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPaxMedica, Inc. Common Stock (PXMD) trades at $0.0005. PaxMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing anti-purinergic drug therapies for complex neurological disorders. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for PXMD: PXMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
PaxMedica, Inc. Common Stock (PXMD) Healthcare & Pipeline Overview
PaxMedica, Inc. specializes in clinical-stage biopharmaceuticals, developing anti-purinergic drug therapies to treat complex neurological disorders, including autism spectrum disorder and long COVID, positioning itself as a key player in addressing significant unmet medical needs.
What Is the Investment Thesis for PXMD?
PaxMedica, Inc. is poised for growth driven by its innovative drug pipeline, particularly with PAX-101 and PAX-102 targeting high-need areas such as autism spectrum disorder and long COVID. With ongoing clinical trials and potential partnerships for development and commercialization, PaxMedica's strategic focus on anti-purinergic therapies could yield substantial returns. However, the company faces challenges typical of clinical-stage biopharmaceuticals, including regulatory hurdles and the need for successful trial outcomes. As of now, PaxMedica's market cap is $0.00B, reflecting its early-stage status, but successful advancements in its drug pipeline could dramatically enhance its valuation in the coming years.
Based on FMP financials and quantitative analysis
PXMD Key Highlights
Market Cap: $0.00B, indicating the company's early-stage development status.
- Beta: -0.56, suggesting lower volatility compared to the market.
- No dividend yield, as the company is reinvesting in clinical development.
- Small workforce of 6 employees, indicating a lean operational model.
- Focus on addressing unmet medical needs in neurological disorders.
Who Are PXMD's Competitors?
PXMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. | $219.72 | -4.96% | $29.4B | 89 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $504.73 | -0.40% | $128B | 97 5-pillar |
| SRPT Sarepta Therapeutics | $17.50 | -0.40% | $1.85B | — |
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PXMD's Key Strengths?
Innovative drug pipeline targeting high-need neurological conditions.
- Strong focus on clinical development and research.
- Agile organizational structure with a small, dedicated team.
What Are PXMD's Weaknesses?
Limited financial resources typical of early-stage biopharmaceutical companies.
- Dependence on successful clinical trial outcomes for future growth.
- Small workforce may limit operational capacity.
What Are the Key Risks for PXMD?
Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles that could delay drug approval timelines.
- Dependence on successful clinical trial outcomes for future growth.
- Competition from established biopharmaceutical companies with more resources.
- Market volatility affecting funding and investor sentiment.
What Are PXMD's Competitive Advantages?
- Innovative focus on anti-purinergic therapies, addressing complex neurological disorders.
- Strong potential market demand for effective treatments in underserved areas.
- Small team allows for agile decision-making and rapid response to market changes.
What Does PXMD Do?
PaxMedica, Inc., incorporated in 2018 and headquartered in Tarrytown, New York, is a biopharmaceutical company dedicated to advancing anti-purinergic drug therapies (APTs). Originally founded as Purinix Pharmaceuticals LLC, the company rebranded to its current name in April 2020 to reflect its focus on innovative treatments for complex neurological disorders characterized by stubborn and persistent symptoms. The company is currently in the clinical development phase, with its lead investigational drug, PAX-101, an intravenous formulation of suramin, being explored for a variety of conditions, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly referred to as long COVID), and human African trypanosomiasis. Additionally, PaxMedica is developing PAX-102, an intranasal version of suramin, aimed at various neurological applications. With a small team of six employees, PaxMedica operates as a subsidiary of Tardimed Sciences LLC, leveraging its parent company's resources and expertise to drive its clinical programs forward. The company is committed to addressing significant gaps in treatment options for patients suffering from debilitating neurological conditions, positioning itself as an innovative player in the biotechnology sector.
What Products and Services Does PXMD Offer?
- Develop anti-purinergic drug therapies for neurological disorders.
- Focus on complex conditions with persistent symptoms.
- Lead product candidate is PAX-101, an intravenous formulation of suramin.
- Exploring treatments for autism spectrum disorder, chronic fatigue syndrome, and long COVID.
- Developing PAX-102, an intranasal version of suramin.
- Operate as a subsidiary of Tardimed Sciences LLC.
How Does PXMD Make Money?
- Generate revenue through the development and potential commercialization of innovative therapies.
- Focus on clinical trials to validate the efficacy of drug candidates.
- Potential partnerships with larger pharmaceutical companies for co-development and distribution.
- Aim to address significant unmet medical needs in the healthcare market.
What Industry Does PXMD Operate In?
The biotechnology industry is experiencing robust growth, driven by increasing demand for innovative therapies and advancements in genetic and cellular research. The market for neurological disorder treatments is expanding, with a growing emphasis on personalized medicine and targeted therapies. PaxMedica, Inc. is positioned within this landscape as it develops anti-purinergic drug therapies, which have the potential to address significant gaps in treatment options for conditions like autism and chronic fatigue syndrome. As the industry continues to evolve, companies like PaxMedica that focus on complex neurological disorders may find increasing opportunities for growth and collaboration.
Who Are PXMD's Key Customers?
- Patients suffering from neurological disorders.
- Healthcare providers seeking effective treatment options.
- Pharmaceutical partners interested in collaboration for drug development.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Earnings Track Record
PaxMedica, Inc. Common Stock has missed Wall Street's EPS estimate in 4 of its last 4 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 35.3% below estimates on average.
Financial Health
PaxMedica, Inc. Common Stock's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
PaxMedica, Inc. Common Stock operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tarrytown, US. The company is led by CEO Howard J. Weisman. PXMD has traded publicly since 2022.
Insider Activity
12 transactions · 0 purchases, 3 sales, 9 other transactions · 7 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
PXMD Financials
PXMD Latest News
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Oct 5, 2023
PXMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PXMD.
Price Targets
Wall Street price target analysis for PXMD.
PXMD MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PXMD; grades run from A+ (80-100) to F (below 30).
Leadership: Howard J. Weisman
CEO
Howard J. Weisman has a distinguished career in the biopharmaceutical industry, with extensive experience in drug development and commercialization. He has held various leadership roles, focusing on advancing innovative therapies and navigating complex regulatory environments. Weisman holds a degree in a relevant field and has been instrumental in guiding PaxMedica's strategic direction since its inception.
Track Record: Under Howard Weisman’s leadership, PaxMedica has made significant strides in developing its drug pipeline, particularly with PAX-101 and PAX-102. His strategic vision has positioned the company to explore critical partnerships and funding opportunities, enhancing its growth potential.
PXMD OTC Market Information
The OTC Other tier represents stocks that are not listed on major exchanges like NYSE or NASDAQ. Companies in this tier may have less stringent reporting requirements, which can lead to lower visibility and liquidity compared to their listed counterparts. This tier often includes smaller or emerging companies, like PaxMedica, that are in early stages of development.
- OTC Tier: OTC Other
- Limited financial disclosures can increase investment risk.
- Lower trading volumes may lead to higher volatility.
- Regulatory uncertainties can impact the company's drug development timelines.
- Verify the company's clinical trial progress and results.
- Assess the management team's experience and track record.
- Review any partnerships or collaborations in place.
- Examine market demand for the company's drug candidates.
- Investigate potential regulatory hurdles that may arise.
- Incorporation as a biopharmaceutical company focused on innovative therapies.
- Rebranding to PaxMedica, Inc. reflects a clear strategic focus.
- Affiliation with Tardimed Sciences LLC provides additional credibility.
PaxMedica, Inc. Common Stock Healthcare Stock: Key Questions Answered
What is PaxMedica, Inc. Common Stock's drug pipeline status?
PaxMedica, Inc. is currently advancing its drug pipeline, with PAX-101 in clinical trials for various indications, including autism spectrum disorder and long COVID.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Company financials are limited due to its OTC classification and early-stage status.